Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 5/2016

02.09.2016 | Review Article

Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives

verfasst von: Ronaldo A. Ribeiro, Carlos W. S. Wanderley, Deysi V. T. Wong, José Maurício S. C. Mota, Caio A. V. G. Leite, Marcellus H. L. P. Souza, Fernando Q. Cunha, Roberto C. P. Lima-Júnior

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Intestinal mucositis and diarrhea are common manifestations of anticancer regimens that include irinotecan, 5-fluorouracil (5-FU), and other cytotoxic drugs. These side effects negatively impact therapeutic outcomes and delay subsequent cycles of chemotherapy, resulting in dose reductions and treatment discontinuation. Here, we aimed to review the experimental evidence regarding possible new targets for the management of irinotecan- and 5-FU-related intestinal mucositis.

Methods

A literature search was performed using the PubMed and MEDLINE databases. No publication time limit was set for article inclusion.

Results

Here, we found that clinical management of intestinal mucositis and diarrhea is somewhat ineffective at reducing symptoms, possibly due to a lack of specific targets for modulation. We observed that IL-1β contributes to the apoptosis of enterocytes in mucositis induced by 5-FU. However, 5-FU-related mucositis is far less thoroughly investigated with regard to specific molecular targets when compared to irinotecan-related disease. Several studies have proposed that a correlation exists between the intestinal microbiota, the enterohepatic recirculation of active metabolites of irinotecan, and the establishment of mucositis. However, as reviewed here, this association seems to be controversial. In addition, the pathogenesis of irinotecan-induced mucositis appears to be orchestrated by interleukin-1/Toll-like receptor family members, leading to epithelial cell apoptosis.

Conclusions

IL-1β, IL-18, and IL-33 and the receptors IL-1R, IL-18R, ST2, and TLR-2 are potential therapeutic targets that can be modulated to minimize anticancer agent-associated toxicity, optimize cancer treatment dosing, and improve clinical outcomes. In this context, the pathogenesis of mucositis caused by other anticancer agents should be further investigated.
Literatur
1.
Zurück zum Zitat Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE et al (2007) Mucositis study section of the multinational association of supportive care in cancer and the international society for oral oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831PubMedCrossRef Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE et al (2007) Mucositis study section of the multinational association of supportive care in cancer and the international society for oral oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831PubMedCrossRef
2.
Zurück zum Zitat Duncan M, Grant G (2003) Oral and intestinal mucositis—causes and possible treatments. Aliment Pharmacol Ther 18:853–874PubMedCrossRef Duncan M, Grant G (2003) Oral and intestinal mucositis—causes and possible treatments. Aliment Pharmacol Ther 18:853–874PubMedCrossRef
3.
Zurück zum Zitat Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS (2006) Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 14(6):505–515PubMedCrossRef Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS (2006) Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 14(6):505–515PubMedCrossRef
4.
Zurück zum Zitat Dranitsaris G, Maroun J, Shah A (2005) Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis. Support Care Cancer 13:318–324PubMedCrossRef Dranitsaris G, Maroun J, Shah A (2005) Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis. Support Care Cancer 13:318–324PubMedCrossRef
5.
Zurück zum Zitat Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J et al (2004) Mucositis study section of the multinational association for supportive care in cancer; international society for oral oncology. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026–2046PubMedCrossRef Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J et al (2004) Mucositis study section of the multinational association for supportive care in cancer; international society for oral oncology. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026–2046PubMedCrossRef
7.
Zurück zum Zitat Avallone A, Di Gennaro E, Silvestro L, Laffaioli VR, Budillon A (2014) Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. Expert Opin Drug Saf 2014(13):113–129CrossRef Avallone A, Di Gennaro E, Silvestro L, Laffaioli VR, Budillon A (2014) Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. Expert Opin Drug Saf 2014(13):113–129CrossRef
8.
Zurück zum Zitat Soares PGM, Mota JMSC, Gomes AS, Oliveira RB, Assreuy AMS, Brito GAC et al (2008) Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution. Cancer Chemother Pharmacol 63:91–98PubMedCrossRef Soares PGM, Mota JMSC, Gomes AS, Oliveira RB, Assreuy AMS, Brito GAC et al (2008) Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution. Cancer Chemother Pharmacol 63:91–98PubMedCrossRef
9.
Zurück zum Zitat Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM (2009) Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 63:239–251PubMedCrossRef Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM (2009) Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 63:239–251PubMedCrossRef
11.
Zurück zum Zitat Yasuda M, Kato S, Yamanaka N, Iimori M, Utsumi D, Kitahara Y et al (2012) Potential role of the NADPH oxidase NOX1 in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. Am J Physiol Gastrointest Liver Physiol 302:G1133–G1142PubMedCrossRef Yasuda M, Kato S, Yamanaka N, Iimori M, Utsumi D, Kitahara Y et al (2012) Potential role of the NADPH oxidase NOX1 in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. Am J Physiol Gastrointest Liver Physiol 302:G1133–G1142PubMedCrossRef
12.
Zurück zum Zitat Wu Z, Han X, Wang Y, Yuan K, Jin Z, Di J et al (2011) Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-Xuorouracil chemotherapy model in mice. Cancer Chemother Pharmacol 68:87–96PubMedCrossRef Wu Z, Han X, Wang Y, Yuan K, Jin Z, Di J et al (2011) Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-Xuorouracil chemotherapy model in mice. Cancer Chemother Pharmacol 68:87–96PubMedCrossRef
13.
Zurück zum Zitat Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914PubMedCrossRef Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914PubMedCrossRef
14.
Zurück zum Zitat Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187–4191PubMed Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187–4191PubMed
16.
Zurück zum Zitat Ma MK, McLeod HL (2003) Lessons learned from the irinotecan metabolic pathway. Curr Med Chem 10:41–49PubMedCrossRef Ma MK, McLeod HL (2003) Lessons learned from the irinotecan metabolic pathway. Curr Med Chem 10:41–49PubMedCrossRef
17.
Zurück zum Zitat Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L et al (2001) Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 6:81–91PubMedCrossRef Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L et al (2001) Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 6:81–91PubMedCrossRef
18.
Zurück zum Zitat Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y et al (1990) An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907–1912PubMed Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y et al (1990) An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907–1912PubMed
19.
Zurück zum Zitat Stein A, Voigt W, Jordan K (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2:51–63PubMedPubMedCentralCrossRef Stein A, Voigt W, Jordan K (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2:51–63PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Andreyev J, Ross P, Donnellan C, Lennan E, Leonard P, Waters C et al (2014) Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol 15:e447–e460PubMedCrossRef Andreyev J, Ross P, Donnellan C, Lennan E, Leonard P, Waters C et al (2014) Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol 15:e447–e460PubMedCrossRef
21.
Zurück zum Zitat Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84:697–702PubMedCrossRef Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84:697–702PubMedCrossRef
22.
Zurück zum Zitat Melo MLP, Brito GAC, Soares RC, Carvalho SB, Silva JV, Soares PM et al (2008) Role of cytokines (TNF-a, IL-1b and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol 61:775–784PubMedCrossRef Melo MLP, Brito GAC, Soares RC, Carvalho SB, Silva JV, Soares PM et al (2008) Role of cytokines (TNF-a, IL-1b and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol 61:775–784PubMedCrossRef
23.
Zurück zum Zitat Dodds HM, Rivory LP (1999) The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). Mol Pharmacol 56:1346–1353PubMed Dodds HM, Rivory LP (1999) The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11). Mol Pharmacol 56:1346–1353PubMed
24.
Zurück zum Zitat Morton CL, Wadkins RM, Danks MK, Potter PM (1999) The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res 59:1458–1463PubMed Morton CL, Wadkins RM, Danks MK, Potter PM (1999) The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res 59:1458–1463PubMed
25.
Zurück zum Zitat Blandizzi C, De Paolis B, Colucci R, Lazzeri G, Baschiera F, Del Tacca M (2001) Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan. Br J Pharmacol 132:73–84PubMedPubMedCentralCrossRef Blandizzi C, De Paolis B, Colucci R, Lazzeri G, Baschiera F, Del Tacca M (2001) Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan. Br J Pharmacol 132:73–84PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Blandizzi D, Danesi R, Paolis B, Di Paolo A, Colucci R, Falcone A et al (2002) Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role. Clin Pharmacol Ther 71:263–271PubMedCrossRef Blandizzi D, Danesi R, Paolis B, Di Paolo A, Colucci R, Falcone A et al (2002) Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role. Clin Pharmacol Ther 71:263–271PubMedCrossRef
27.
Zurück zum Zitat Hecht R (1998) Gastrointestinal toxicity of irinotecan. Oncology 12:73–78 Hecht R (1998) Gastrointestinal toxicity of irinotecan. Oncology 12:73–78
28.
Zurück zum Zitat Lima-Júnior RCP, Figueiredo AA, Freitas HC, Melo ML, Wong DV, Leite CA et al (2012) Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation. Cancer Chemother Pharmacol 69:931–942PubMedCrossRef Lima-Júnior RCP, Figueiredo AA, Freitas HC, Melo ML, Wong DV, Leite CA et al (2012) Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation. Cancer Chemother Pharmacol 69:931–942PubMedCrossRef
29.
Zurück zum Zitat Lima-Júnior RCP, Freitas HC, Wong DVT, Wanderley CW, Nunes LG, Leite LL et al (2014) Targeted inhibition of IL-18 attenuates irinotecan induced intestinal mucositis in mice. Br J Pharmacol 171:2335–2350PubMedPubMedCentralCrossRef Lima-Júnior RCP, Freitas HC, Wong DVT, Wanderley CW, Nunes LG, Leite LL et al (2014) Targeted inhibition of IL-18 attenuates irinotecan induced intestinal mucositis in mice. Br J Pharmacol 171:2335–2350PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Wong DV, Lima-Júnior RC, Carvalho CB, Borges VF, Wanderley CW, Bem AX et al (2015) The adaptor protein Myd88 is a key signaling molecule in the pathogenesis of irinotecan-induced intestinal mucositis. PLoS ONE 10:e0139985PubMedPubMedCentralCrossRef Wong DV, Lima-Júnior RC, Carvalho CB, Borges VF, Wanderley CW, Bem AX et al (2015) The adaptor protein Myd88 is a key signaling molecule in the pathogenesis of irinotecan-induced intestinal mucositis. PLoS ONE 10:e0139985PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S et al (2008) Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 10:216–222PubMedPubMedCentralCrossRef Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S et al (2008) Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 10:216–222PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E et al (1998) Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 42:280–286PubMedCrossRef Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E et al (1998) Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 42:280–286PubMedCrossRef
33.
Zurück zum Zitat Itoh T, Takemoto I (2004) Biliary excretion of irinotecan and its metabolites. J Pharm Pharm Sci 7:13–18PubMed Itoh T, Takemoto I (2004) Biliary excretion of irinotecan and its metabolites. J Pharm Pharm Sci 7:13–18PubMed
34.
Zurück zum Zitat Takasuna KTH, Hirohashi M, Kato M, Kato M, Nomura M, Nagai E et al (1996) Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752–3757PubMed Takasuna KTH, Hirohashi M, Kato M, Kato M, Nomura M, Nagai E et al (1996) Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752–3757PubMed
35.
Zurück zum Zitat Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Keefe DM (2008) Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther 7:1919–1925PubMedCrossRef Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Keefe DM (2008) Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther 7:1919–1925PubMedCrossRef
36.
Zurück zum Zitat Sezer A, Ust U, Cicin I (2009) The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea. Med Oncol 26:350–357PubMedCrossRef Sezer A, Ust U, Cicin I (2009) The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea. Med Oncol 26:350–357PubMedCrossRef
37.
Zurück zum Zitat Roberts AB, Wallace BD, Venkatesh MK, Mani S, Redinbo MR et al (2013) Molecular insights into microbial β-glucoronidase inhibition to abrogate CPT-11 toxicity. Mol Pharmacol 84:208–217PubMedPubMedCentralCrossRef Roberts AB, Wallace BD, Venkatesh MK, Mani S, Redinbo MR et al (2013) Molecular insights into microbial β-glucoronidase inhibition to abrogate CPT-11 toxicity. Mol Pharmacol 84:208–217PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Kehrer DFC, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J et al (2001) Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 7:1136–1141PubMed Kehrer DFC, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J et al (2001) Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 7:1136–1141PubMed
39.
Zurück zum Zitat Kurita A, Kado S, Matsumoto T, Asakawa N, Kaneda N, Kato I et al (2011) Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen. Cancer Chemother Pharmacol 67:201–213PubMedCrossRef Kurita A, Kado S, Matsumoto T, Asakawa N, Kaneda N, Kato I et al (2011) Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen. Cancer Chemother Pharmacol 67:201–213PubMedCrossRef
40.
Zurück zum Zitat Pedroso SH, Vieira AT, Bastos RW, Oliveira JS, Cartelle CT, Arantes RM et al (2015) Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. Microbiology 161:1950–1960PubMedCrossRef Pedroso SH, Vieira AT, Bastos RW, Oliveira JS, Cartelle CT, Arantes RM et al (2015) Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. Microbiology 161:1950–1960PubMedCrossRef
41.
Zurück zum Zitat Brandi G, Dabard J, Raibaud P, Di Battista M, Bridonneau C, Pisi AM et al (2006) Intestinal microflora and digestive toxicity of irinotecan in mice. Clin Cancer Res 12:1299–1307PubMedCrossRef Brandi G, Dabard J, Raibaud P, Di Battista M, Bridonneau C, Pisi AM et al (2006) Intestinal microflora and digestive toxicity of irinotecan in mice. Clin Cancer Res 12:1299–1307PubMedCrossRef
42.
Zurück zum Zitat Ikuno N, Soda H, Watanabe M, Oka M (1995) Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 87(24):1876–1883PubMedCrossRef Ikuno N, Soda H, Watanabe M, Oka M (1995) Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 87(24):1876–1883PubMedCrossRef
43.
Zurück zum Zitat Sparreboom A, De Jonge MJ, De Bruijn P, Brouwer E, Nooter K, Loos WJ et al (1998) Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 4:2747–2754PubMed Sparreboom A, De Jonge MJ, De Bruijn P, Brouwer E, Nooter K, Loos WJ et al (1998) Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 4:2747–2754PubMed
44.
Zurück zum Zitat Ulukan H, Muller MT, Swaan PW (2001) Downregulation of topoisomerase I in differentiating human intestinal epithelial cells. Int J Cancer 94:200–207PubMedCrossRef Ulukan H, Muller MT, Swaan PW (2001) Downregulation of topoisomerase I in differentiating human intestinal epithelial cells. Int J Cancer 94:200–207PubMedCrossRef
45.
Zurück zum Zitat Bowen JM, Gibson RJ, Cummins AG (2006) Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer 14:713–731PubMedCrossRef Bowen JM, Gibson RJ, Cummins AG (2006) Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer 14:713–731PubMedCrossRef
46.
Zurück zum Zitat Tsujimoto Y (1998) Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells 3:697–707PubMedCrossRef Tsujimoto Y (1998) Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells 3:697–707PubMedCrossRef
47.
Zurück zum Zitat Besbes S, Mirshahi M, Pocard M, Billard C (2015) New dimension in therapeutic targeting of BCL-2 family proteins. Oncotarget 30:12862–12871CrossRef Besbes S, Mirshahi M, Pocard M, Billard C (2015) New dimension in therapeutic targeting of BCL-2 family proteins. Oncotarget 30:12862–12871CrossRef
48.
Zurück zum Zitat Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC (1994) Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 145:1323–1336PubMedPubMedCentral Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC (1994) Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 145:1323–1336PubMedPubMedCentral
49.
Zurück zum Zitat Bowen JM, Gibson RJ, Tsykin A, Stringer AM, Logan RM, Keefe DM (2007) Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. Int J Cancer 121:1847–1856PubMedCrossRef Bowen JM, Gibson RJ, Tsykin A, Stringer AM, Logan RM, Keefe DM (2007) Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. Int J Cancer 121:1847–1856PubMedCrossRef
50.
Zurück zum Zitat Bowen JM, Tsykin A, Stringer AM, Logan RM, Gibson RJ, Keefe DM (2010) Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract. Toxicology 269:1–12PubMedCrossRef Bowen JM, Tsykin A, Stringer AM, Logan RM, Gibson RJ, Keefe DM (2010) Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract. Toxicology 269:1–12PubMedCrossRef
51.
Zurück zum Zitat Czabotar PE, Lessene G, Strasser A, Adams JM (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15:49–63PubMedCrossRef Czabotar PE, Lessene G, Strasser A, Adams JM (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15:49–63PubMedCrossRef
52.
Zurück zum Zitat Bowen JM, Gibson RJ, Stringer AM, Chan TW, Prabowo AS, Cummins AG et al (2007) Role of p53 in irinotecan-induced intestinal cell death and mucosal damage. Anticancer Drugs 18:197–210PubMedCrossRef Bowen JM, Gibson RJ, Stringer AM, Chan TW, Prabowo AS, Cummins AG et al (2007) Role of p53 in irinotecan-induced intestinal cell death and mucosal damage. Anticancer Drugs 18:197–210PubMedCrossRef
54.
Zurück zum Zitat Chowdhury I, Tharakan B, Bhat GK (2008) Caspases—an update. Comp Biochem Physiol 151:10–27CrossRef Chowdhury I, Tharakan B, Bhat GK (2008) Caspases—an update. Comp Biochem Physiol 151:10–27CrossRef
55.
Zurück zum Zitat Arifa RDN, Madeira MF, de Paula TP, Lima RL, Tavares LD, Menezes-Garcia Z et al (2014) Inflammasome activation is reactive oxygen species dependent and mediates irinotecan-induced mucositis through IL-1b and IL-18 in mice. Am J Pathol 184:2023–2034PubMedCrossRef Arifa RDN, Madeira MF, de Paula TP, Lima RL, Tavares LD, Menezes-Garcia Z et al (2014) Inflammasome activation is reactive oxygen species dependent and mediates irinotecan-induced mucositis through IL-1b and IL-18 in mice. Am J Pathol 184:2023–2034PubMedCrossRef
56.
Zurück zum Zitat Wang X, Zhub S, Qiana L, Gao J, Wu M, Gao J et al (2014) IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21WAF1and p27KIP1. Pharmacol Res 82:21–33PubMedCrossRef Wang X, Zhub S, Qiana L, Gao J, Wu M, Gao J et al (2014) IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21WAF1and p27KIP1. Pharmacol Res 82:21–33PubMedCrossRef
57.
Zurück zum Zitat Guabiraba R, Besnard AG, Menezes GB, Secher T, Jabir MS, Amaral SS et al (2014) IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice. Mucosal Immunol 7:1079–1093PubMedPubMedCentralCrossRef Guabiraba R, Besnard AG, Menezes GB, Secher T, Jabir MS, Amaral SS et al (2014) IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice. Mucosal Immunol 7:1079–1093PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Bohnenkamp HR, Papazisis KT, Burchell JM, Taylor-Papadimitriou J (2007) Synergism of toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. Cell Immunol 247:72–84PubMedCrossRef Bohnenkamp HR, Papazisis KT, Burchell JM, Taylor-Papadimitriou J (2007) Synergism of toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. Cell Immunol 247:72–84PubMedCrossRef
59.
Zurück zum Zitat Frosali S, Pagliari D, Gambassi G, Landolfi R, Pandolfi F, Cianci R (2015) How the intricate interaction among toll-like receptors, microbiota, and intestinal immunity can influence gastrointestinal pathology. J Immunol Res 2015:489821PubMedPubMedCentralCrossRef Frosali S, Pagliari D, Gambassi G, Landolfi R, Pandolfi F, Cianci R (2015) How the intricate interaction among toll-like receptors, microbiota, and intestinal immunity can influence gastrointestinal pathology. J Immunol Res 2015:489821PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM (2007) Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 7:1271–1285PubMedCrossRef Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM (2007) Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 7:1271–1285PubMedCrossRef
61.
Zurück zum Zitat Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81:1–5PubMedCrossRef Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81:1–5PubMedCrossRef
62.
Zurück zum Zitat Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2:675–680PubMedCrossRef Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2:675–680PubMedCrossRef
64.
Zurück zum Zitat Fernandes P, MacSharry J, Darby T, Fanning A, Shanahan F, Houston A et al (2015) Differential expression of key regulators of toll-like receptors in ulcerative Colitis and Crohn’s disease: a role for Tollip and PPARγ. Clin Exp Immunol. doi:10.1111/cei.12732 PubMed Fernandes P, MacSharry J, Darby T, Fanning A, Shanahan F, Houston A et al (2015) Differential expression of key regulators of toll-like receptors in ulcerative Colitis and Crohn’s disease: a role for Tollip and PPARγ. Clin Exp Immunol. doi:10.​1111/​cei.​12732 PubMed
65.
Zurück zum Zitat Fan Y, Liu B (2015) Expression of toll-like receptors in the mucosa of patients with ulcerative colitis. Exp Ther Med 9:1455–1459PubMedPubMedCentral Fan Y, Liu B (2015) Expression of toll-like receptors in the mucosa of patients with ulcerative colitis. Exp Ther Med 9:1455–1459PubMedPubMedCentral
66.
Zurück zum Zitat Lu CC, Kuo HC, Wang FS, Jou MH, Lee KC, Chuang JH (2014) Upregulation of TLRs and IL-6 as a marker in human colorectal cancer. Int J Mol Sci 16:159–177PubMedPubMedCentralCrossRef Lu CC, Kuo HC, Wang FS, Jou MH, Lee KC, Chuang JH (2014) Upregulation of TLRs and IL-6 as a marker in human colorectal cancer. Int J Mol Sci 16:159–177PubMedPubMedCentralCrossRef
67.
Zurück zum Zitat Kaczmarek A, Brinkman BM, Heyndrickx L, Vandenabeele P, Krysko DV (2012) Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways. J Pathol 226:598–608PubMedCrossRef Kaczmarek A, Brinkman BM, Heyndrickx L, Vandenabeele P, Krysko DV (2012) Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways. J Pathol 226:598–608PubMedCrossRef
68.
Zurück zum Zitat Frank M, Hennenberg EM, Eyking A, Rünzi M, Gerken G, Scott P et al (2015) TLR signaling modulates side effects of anticancer therapy in the small intestine. J Immunol 194:1983–1995PubMedPubMedCentralCrossRef Frank M, Hennenberg EM, Eyking A, Rünzi M, Gerken G, Scott P et al (2015) TLR signaling modulates side effects of anticancer therapy in the small intestine. J Immunol 194:1983–1995PubMedPubMedCentralCrossRef
69.
Zurück zum Zitat Ribeiro RA, Lima-Junior RC, Leite CAV, Mota JMS, Macedo FY, Lima MV et al (2012) Chemotherapy-induced hemorrhagic cystitis: pathogenesis, pharmacological approaches and new insights. J Exp Integr Med 2:95–112 Ribeiro RA, Lima-Junior RC, Leite CAV, Mota JMS, Macedo FY, Lima MV et al (2012) Chemotherapy-induced hemorrhagic cystitis: pathogenesis, pharmacological approaches and new insights. J Exp Integr Med 2:95–112
70.
Zurück zum Zitat Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS et al (2002) Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 62:5778–5784PubMed Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS et al (2002) Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 62:5778–5784PubMed
71.
Zurück zum Zitat Javle MM, Cao S, Durrani FA, Pendyala L, Lawrence DD, Smith PF et al (2007) Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Clin Cancer Res 13:965–971PubMedCrossRef Javle MM, Cao S, Durrani FA, Pendyala L, Lawrence DD, Smith PF et al (2007) Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Clin Cancer Res 13:965–971PubMedCrossRef
72.
Zurück zum Zitat Leitão RF, Ribeiro RA, Bellaguarda EA, Macedo FD, Silva LR, Oriá RB et al (2007) Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster. Cancer Chemother Pharmacol 59:603–612PubMedCrossRef Leitão RF, Ribeiro RA, Bellaguarda EA, Macedo FD, Silva LR, Oriá RB et al (2007) Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster. Cancer Chemother Pharmacol 59:603–612PubMedCrossRef
73.
Zurück zum Zitat Leitão RF, Brito GA, Oriá RB, Braga-Neto MB, Bellaguarda EA, Silva JV et al (2011) Role of inducible nitric oxide synthase pathway on methotrexate-induced intestinal mucositis in rodents. BMC Gastroenterol 16:11–90 Leitão RF, Brito GA, Oriá RB, Braga-Neto MB, Bellaguarda EA, Silva JV et al (2011) Role of inducible nitric oxide synthase pathway on methotrexate-induced intestinal mucositis in rodents. BMC Gastroenterol 16:11–90
74.
Zurück zum Zitat Van Sebille YZ, Stansborough R, Wardill HR, Bateman E, Gibson RJ, Keefe DM (2015) Management of mucositis during chemotherapy: from pathophysiology to pragmatic therapeutics. Curr Oncol Rep 17:50PubMedCrossRef Van Sebille YZ, Stansborough R, Wardill HR, Bateman E, Gibson RJ, Keefe DM (2015) Management of mucositis during chemotherapy: from pathophysiology to pragmatic therapeutics. Curr Oncol Rep 17:50PubMedCrossRef
76.
Zurück zum Zitat Peterson DE, Bensadoun RJ, Roila F, ESMO Guidelines Working Group (2009) Management of oral and gastrointestinal mucositis: ESMO clinical recommendations. Ann Oncol 20:174–177PubMedCrossRef Peterson DE, Bensadoun RJ, Roila F, ESMO Guidelines Working Group (2009) Management of oral and gastrointestinal mucositis: ESMO clinical recommendations. Ann Oncol 20:174–177PubMedCrossRef
77.
Zurück zum Zitat Ychou M, Douillard JY, Rougier P, Adenis A, Mousseau M, Dufour P et al (2000) Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. Am J Clin Oncol 23:143–148PubMedCrossRef Ychou M, Douillard JY, Rougier P, Adenis A, Mousseau M, Dufour P et al (2000) Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. Am J Clin Oncol 23:143–148PubMedCrossRef
78.
Zurück zum Zitat Karthaus M, Ballo H, Abenhardt W, Steinmetz T, Geer T, Schimke J et al (2005) Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. Oncology 68:326–332PubMedCrossRef Karthaus M, Ballo H, Abenhardt W, Steinmetz T, Geer T, Schimke J et al (2005) Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. Oncology 68:326–332PubMedCrossRef
79.
Zurück zum Zitat Gibson RJ, Bowen JM, Keefe DMK (2005) Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 116:464–470PubMedCrossRef Gibson RJ, Bowen JM, Keefe DMK (2005) Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 116:464–470PubMedCrossRef
80.
Zurück zum Zitat Heel RC, Brogden RN, Speight TM, Avery GS (1978) Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea. Drugs 15:33–52PubMedCrossRef Heel RC, Brogden RN, Speight TM, Avery GS (1978) Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea. Drugs 15:33–52PubMedCrossRef
81.
Zurück zum Zitat Sharma R, Tobin P, Clarke SJ (2005) Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 6:93–102PubMedCrossRef Sharma R, Tobin P, Clarke SJ (2005) Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 6:93–102PubMedCrossRef
82.
Zurück zum Zitat Regnard C, Twycross R, Mihalyo M, Wilcock A (2011) Loperamide. J Pain Symptom Manag 42:319–323CrossRef Regnard C, Twycross R, Mihalyo M, Wilcock A (2011) Loperamide. J Pain Symptom Manag 42:319–323CrossRef
84.
Zurück zum Zitat Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC et al (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709–715PubMed Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC et al (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709–715PubMed
85.
Zurück zum Zitat Vamvakas L, Kakolyris S, Kouroussis C, Kandilis K, Mavroudis D, Ziras N, Greek Colorectal Cooperative Oncology Group. et al (2002) Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. Am J Clin Oncol 25:65–70PubMedCrossRef Vamvakas L, Kakolyris S, Kouroussis C, Kandilis K, Mavroudis D, Ziras N, Greek Colorectal Cooperative Oncology Group. et al (2002) Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. Am J Clin Oncol 25:65–70PubMedCrossRef
86.
Zurück zum Zitat Sun L, Coy DH (2014) Somatostatin and its analogs. Curr Drug Targets. [Epub ahead of print] Sun L, Coy DH (2014) Somatostatin and its analogs. Curr Drug Targets. [Epub ahead of print]
87.
Zurück zum Zitat Sun JX, Yang N (2014) Role of octreotide in post chemotherapy and/or radiotherapy diarrhea: prophylaxis or therapy? Asia Pac J Clin Oncol 10:e108–e113PubMedCrossRef Sun JX, Yang N (2014) Role of octreotide in post chemotherapy and/or radiotherapy diarrhea: prophylaxis or therapy? Asia Pac J Clin Oncol 10:e108–e113PubMedCrossRef
88.
Zurück zum Zitat Ruskone A, Rene E, Chayvialle JA, Bonin N, Pignal F, Kremer M et al (1982) Effect of soma-tostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. Dig Dis Sci 27:459–466PubMedCrossRef Ruskone A, Rene E, Chayvialle JA, Bonin N, Pignal F, Kremer M et al (1982) Effect of soma-tostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. Dig Dis Sci 27:459–466PubMedCrossRef
89.
Zurück zum Zitat Barbounis V, Koumakis G, Vassilomanolakis M, Demiri M, Efremidis AP (2001) Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 9:258–260PubMedCrossRef Barbounis V, Koumakis G, Vassilomanolakis M, Demiri M, Efremidis AP (2001) Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 9:258–260PubMedCrossRef
90.
Zurück zum Zitat Bhattacharya S, Vijayasekar C, Worlding J, Mathew G (2009) Octreotide in chemotherapy induced diarrhoea in colorectal cancer: a review article. Acta Gastroenterol Belg 72:289–295PubMed Bhattacharya S, Vijayasekar C, Worlding J, Mathew G (2009) Octreotide in chemotherapy induced diarrhoea in colorectal cancer: a review article. Acta Gastroenterol Belg 72:289–295PubMed
91.
Zurück zum Zitat Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Burns J et al (2007) Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med 232:96–106 Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Burns J et al (2007) Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med 232:96–106
92.
Zurück zum Zitat Schmittel A, Jahnke K, Thiel E, Keilholz U (2004) Neomycin as secondary prophylaxis for irinotecan-induced diarrhea. Ann Oncol 15:1296PubMedCrossRef Schmittel A, Jahnke K, Thiel E, Keilholz U (2004) Neomycin as secondary prophylaxis for irinotecan-induced diarrhea. Ann Oncol 15:1296PubMedCrossRef
93.
Zurück zum Zitat Alimonti A, Satta F, Pavese I, Burattini E, Zoffoli V, Vecchione A (2003) Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann Oncol 14:805–806PubMedCrossRef Alimonti A, Satta F, Pavese I, Burattini E, Zoffoli V, Vecchione A (2003) Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann Oncol 14:805–806PubMedCrossRef
94.
Zurück zum Zitat Mani S, Boelsterli UA, Redinbo MR (2014) Understanding and modulating mammalian-microbial communication for improved human health. Annu Rev Pharmacol Toxicol 54:559–580PubMedCrossRef Mani S, Boelsterli UA, Redinbo MR (2014) Understanding and modulating mammalian-microbial communication for improved human health. Annu Rev Pharmacol Toxicol 54:559–580PubMedCrossRef
95.
Zurück zum Zitat Pérez-Cobas AE, Gosalbes MJ, Friedrichs A, Knecht H, Artacho A, Eismann K et al (2013) Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut 62:1591–1601PubMedCrossRef Pérez-Cobas AE, Gosalbes MJ, Friedrichs A, Knecht H, Artacho A, Eismann K et al (2013) Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut 62:1591–1601PubMedCrossRef
96.
Zurück zum Zitat Costa CL, Quesada-Gómez C, de Carvalho CB, González RH, Gifoni MA, Ribeiro RA et al (2014) Community-acquired diarrhea associated with clostridium difficile in an HIV-positive cancer patient: first case report in Latin America. Int J Infect Dis 26:138–139PubMedCrossRef Costa CL, Quesada-Gómez C, de Carvalho CB, González RH, Gifoni MA, Ribeiro RA et al (2014) Community-acquired diarrhea associated with clostridium difficile in an HIV-positive cancer patient: first case report in Latin America. Int J Infect Dis 26:138–139PubMedCrossRef
97.
98.
Zurück zum Zitat Touchefeu Y, Montassier E, Nieman K, Gastinne T, Potel G, Bruley des Varannes S et al (2014) Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis—current evidence and potential clinical applications. Aliment Pharmacol Ther 40:409–421PubMed Touchefeu Y, Montassier E, Nieman K, Gastinne T, Potel G, Bruley des Varannes S et al (2014) Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis—current evidence and potential clinical applications. Aliment Pharmacol Ther 40:409–421PubMed
99.
Zurück zum Zitat Bowen JM, Stringer AM, Gibson RJ, Yeoh AS, Hannam S, Keefe DM (2007) VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 6:1449–1454PubMedCrossRef Bowen JM, Stringer AM, Gibson RJ, Yeoh AS, Hannam S, Keefe DM (2007) VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 6:1449–1454PubMedCrossRef
100.
Zurück zum Zitat Osterlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P et al (2007) Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 97:1028–1034PubMedPubMedCentralCrossRef Osterlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P et al (2007) Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 97:1028–1034PubMedPubMedCentralCrossRef
101.
Zurück zum Zitat Wada M, Nagata S, Saito M, Shimizu T, Yamashiro Y, Matsuki T et al (2010) Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies. Support Care Cancer 18:751–759PubMedCrossRef Wada M, Nagata S, Saito M, Shimizu T, Yamashiro Y, Matsuki T et al (2010) Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies. Support Care Cancer 18:751–759PubMedCrossRef
102.
Zurück zum Zitat Sakai H, Diener M, Gartmann V, Takeguchi N (1995) Eicosanoid-mediated Cl− secretion induced by the antitumor drug, irinotecan (CPT-11), in the rat colon. Naunyn-Schmiedeberg’s Arch Pharmacol 351:309–314CrossRef Sakai H, Diener M, Gartmann V, Takeguchi N (1995) Eicosanoid-mediated Cl secretion induced by the antitumor drug, irinotecan (CPT-11), in the rat colon. Naunyn-Schmiedeberg’s Arch Pharmacol 351:309–314CrossRef
103.
Zurück zum Zitat Cao S, Black JD, Troutt AB, Rustum YM (1998) Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res 58:3270–3274PubMed Cao S, Black JD, Troutt AB, Rustum YM (1998) Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res 58:3270–3274PubMed
104.
Zurück zum Zitat Ikegami T, Ha L, Arimori K, Latham P, Kobayashi K, Ceryak S et al (2002) Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 62:179–187PubMed Ikegami T, Ha L, Arimori K, Latham P, Kobayashi K, Ceryak S et al (2002) Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 62:179–187PubMed
105.
Zurück zum Zitat Yang XX, Hu ZP, Xu AL, Duan W, Zhu YZ, Huang M et al (2006) A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-a inhibitor. J Pharmacol Exp Ther 319:82–104PubMedCrossRef Yang XX, Hu ZP, Xu AL, Duan W, Zhu YZ, Huang M et al (2006) A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-a inhibitor. J Pharmacol Exp Ther 319:82–104PubMedCrossRef
106.
Zurück zum Zitat Xue H, Sawyer MB, Field CJ, Dieleman LA, Baracos VE (2007) Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor. Clin Cancer Res 13:7146-7154PubMedCrossRef Xue H, Sawyer MB, Field CJ, Dieleman LA, Baracos VE (2007) Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor. Clin Cancer Res 13:7146-7154PubMedCrossRef
107.
Zurück zum Zitat Chen S, Yueha MF, Bigob C, Barbier O, Wang K, Karin M et al (2013) Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11). Proc Natl Acad Sci USA 110:19143–19148PubMedPubMedCentralCrossRef Chen S, Yueha MF, Bigob C, Barbier O, Wang K, Karin M et al (2013) Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11). Proc Natl Acad Sci USA 110:19143–19148PubMedPubMedCentralCrossRef
Metadaten
Titel
Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives
verfasst von
Ronaldo A. Ribeiro
Carlos W. S. Wanderley
Deysi V. T. Wong
José Maurício S. C. Mota
Caio A. V. G. Leite
Marcellus H. L. P. Souza
Fernando Q. Cunha
Roberto C. P. Lima-Júnior
Publikationsdatum
02.09.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 5/2016
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-016-3139-y

Weitere Artikel der Ausgabe 5/2016

Cancer Chemotherapy and Pharmacology 5/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.